Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia

Abhishek A. Singh, Francesca Petraglia, Angela Nebbioso, Guoqiang Yi, Mariarosaria Conte, Sergio Valente, Amit Mandoli, Lucia Scisciola, Rik Lindeboom, Hinri Kerstens, Eva M. Janssen-Megens, Farzin Pourfarzad, Ehsan Habibi, Kim Berentsen, Bowon Kim, Colin Logie, Simon Heath, Albertus T.J. Wierenga, Laura Clarke, Paul FlicekJoop H. Jansen, Taco Kuijpers, Marie Laure Yaspo, Veronique Della Valle, Olivier Bernard, Ivo Gut, Edo Vellenga, Hendrik G. Stunnenberg, Antonello Mai, Lucia Altucci, Joost H.A. Martens

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epigenomic alterations have been associated with both pathogenesis and progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) patients and compared it to non-high-risk APL cases. Despite the lack of common genetic signatures, we found that human hrAPL blasts from patients with extremely poor prognosis display specific patterns of histone H3 acetylation, specifically hyperacetylation at a common set of enhancer regions. In addition, unique profiles of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these could be further developed into markers for clinical identification. The epigenetic drug MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of highrisk APL blasts and reshapes their epigenomes by targeting both active and repressive marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL patients, and provides proof of concept for use of epigenome profiling coupled to epigenetic drugs to 'personalize' precision medicine.

Original languageEnglish
Pages (from-to)25647-25660
Number of pages14
JournalOncotarget
Volume9
Issue number39
DOIs
Publication statusPublished - May 22 2018

Fingerprint

Acute Promyelocytic Leukemia
Epigenomics
Precision Medicine
DNA Methylation
Acetylation
Histones
Pharmaceutical Preparations
Biomarkers
Apoptosis

Keywords

  • Acute promyelocytic leukemia (APL)
  • Epi-drugs
  • Epigenome
  • High-risk APL
  • PML-RARA

ASJC Scopus subject areas

  • Oncology

Cite this

Singh, A. A., Petraglia, F., Nebbioso, A., Yi, G., Conte, M., Valente, S., ... Martens, J. H. A. (2018). Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 9(39), 25647-25660. https://doi.org/10.18632/oncotarget.25429

Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. / Singh, Abhishek A.; Petraglia, Francesca; Nebbioso, Angela; Yi, Guoqiang; Conte, Mariarosaria; Valente, Sergio; Mandoli, Amit; Scisciola, Lucia; Lindeboom, Rik; Kerstens, Hinri; Janssen-Megens, Eva M.; Pourfarzad, Farzin; Habibi, Ehsan; Berentsen, Kim; Kim, Bowon; Logie, Colin; Heath, Simon; Wierenga, Albertus T.J.; Clarke, Laura; Flicek, Paul; Jansen, Joop H.; Kuijpers, Taco; Yaspo, Marie Laure; Della Valle, Veronique; Bernard, Olivier; Gut, Ivo; Vellenga, Edo; Stunnenberg, Hendrik G.; Mai, Antonello; Altucci, Lucia; Martens, Joost H.A.

In: Oncotarget, Vol. 9, No. 39, 22.05.2018, p. 25647-25660.

Research output: Contribution to journalArticle

Singh, AA, Petraglia, F, Nebbioso, A, Yi, G, Conte, M, Valente, S, Mandoli, A, Scisciola, L, Lindeboom, R, Kerstens, H, Janssen-Megens, EM, Pourfarzad, F, Habibi, E, Berentsen, K, Kim, B, Logie, C, Heath, S, Wierenga, ATJ, Clarke, L, Flicek, P, Jansen, JH, Kuijpers, T, Yaspo, ML, Della Valle, V, Bernard, O, Gut, I, Vellenga, E, Stunnenberg, HG, Mai, A, Altucci, L & Martens, JHA 2018, 'Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia', Oncotarget, vol. 9, no. 39, pp. 25647-25660. https://doi.org/10.18632/oncotarget.25429
Singh, Abhishek A. ; Petraglia, Francesca ; Nebbioso, Angela ; Yi, Guoqiang ; Conte, Mariarosaria ; Valente, Sergio ; Mandoli, Amit ; Scisciola, Lucia ; Lindeboom, Rik ; Kerstens, Hinri ; Janssen-Megens, Eva M. ; Pourfarzad, Farzin ; Habibi, Ehsan ; Berentsen, Kim ; Kim, Bowon ; Logie, Colin ; Heath, Simon ; Wierenga, Albertus T.J. ; Clarke, Laura ; Flicek, Paul ; Jansen, Joop H. ; Kuijpers, Taco ; Yaspo, Marie Laure ; Della Valle, Veronique ; Bernard, Olivier ; Gut, Ivo ; Vellenga, Edo ; Stunnenberg, Hendrik G. ; Mai, Antonello ; Altucci, Lucia ; Martens, Joost H.A. / Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. In: Oncotarget. 2018 ; Vol. 9, No. 39. pp. 25647-25660.
@article{1337776331fa45638d01e6730ab46257,
title = "Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia",
abstract = "Epigenomic alterations have been associated with both pathogenesis and progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) patients and compared it to non-high-risk APL cases. Despite the lack of common genetic signatures, we found that human hrAPL blasts from patients with extremely poor prognosis display specific patterns of histone H3 acetylation, specifically hyperacetylation at a common set of enhancer regions. In addition, unique profiles of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these could be further developed into markers for clinical identification. The epigenetic drug MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of highrisk APL blasts and reshapes their epigenomes by targeting both active and repressive marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL patients, and provides proof of concept for use of epigenome profiling coupled to epigenetic drugs to 'personalize' precision medicine.",
keywords = "Acute promyelocytic leukemia (APL), Epi-drugs, Epigenome, High-risk APL, PML-RARA",
author = "Singh, {Abhishek A.} and Francesca Petraglia and Angela Nebbioso and Guoqiang Yi and Mariarosaria Conte and Sergio Valente and Amit Mandoli and Lucia Scisciola and Rik Lindeboom and Hinri Kerstens and Janssen-Megens, {Eva M.} and Farzin Pourfarzad and Ehsan Habibi and Kim Berentsen and Bowon Kim and Colin Logie and Simon Heath and Wierenga, {Albertus T.J.} and Laura Clarke and Paul Flicek and Jansen, {Joop H.} and Taco Kuijpers and Yaspo, {Marie Laure} and {Della Valle}, Veronique and Olivier Bernard and Ivo Gut and Edo Vellenga and Stunnenberg, {Hendrik G.} and Antonello Mai and Lucia Altucci and Martens, {Joost H.A.}",
year = "2018",
month = "5",
day = "22",
doi = "10.18632/oncotarget.25429",
language = "English",
volume = "9",
pages = "25647--25660",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "39",

}

TY - JOUR

T1 - Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia

AU - Singh, Abhishek A.

AU - Petraglia, Francesca

AU - Nebbioso, Angela

AU - Yi, Guoqiang

AU - Conte, Mariarosaria

AU - Valente, Sergio

AU - Mandoli, Amit

AU - Scisciola, Lucia

AU - Lindeboom, Rik

AU - Kerstens, Hinri

AU - Janssen-Megens, Eva M.

AU - Pourfarzad, Farzin

AU - Habibi, Ehsan

AU - Berentsen, Kim

AU - Kim, Bowon

AU - Logie, Colin

AU - Heath, Simon

AU - Wierenga, Albertus T.J.

AU - Clarke, Laura

AU - Flicek, Paul

AU - Jansen, Joop H.

AU - Kuijpers, Taco

AU - Yaspo, Marie Laure

AU - Della Valle, Veronique

AU - Bernard, Olivier

AU - Gut, Ivo

AU - Vellenga, Edo

AU - Stunnenberg, Hendrik G.

AU - Mai, Antonello

AU - Altucci, Lucia

AU - Martens, Joost H.A.

PY - 2018/5/22

Y1 - 2018/5/22

N2 - Epigenomic alterations have been associated with both pathogenesis and progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) patients and compared it to non-high-risk APL cases. Despite the lack of common genetic signatures, we found that human hrAPL blasts from patients with extremely poor prognosis display specific patterns of histone H3 acetylation, specifically hyperacetylation at a common set of enhancer regions. In addition, unique profiles of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these could be further developed into markers for clinical identification. The epigenetic drug MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of highrisk APL blasts and reshapes their epigenomes by targeting both active and repressive marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL patients, and provides proof of concept for use of epigenome profiling coupled to epigenetic drugs to 'personalize' precision medicine.

AB - Epigenomic alterations have been associated with both pathogenesis and progression of cancer. Here, we analyzed the epigenome of two high-risk APL (hrAPL) patients and compared it to non-high-risk APL cases. Despite the lack of common genetic signatures, we found that human hrAPL blasts from patients with extremely poor prognosis display specific patterns of histone H3 acetylation, specifically hyperacetylation at a common set of enhancer regions. In addition, unique profiles of the repressive marks H3K27me3 and DNA methylation were exposed in high-risk APLs. Epigenetic comparison with low/intermediate-risk APLs and AMLs revealed hrAPL-specific patterns of histone acetylation and DNA methylation, suggesting these could be further developed into markers for clinical identification. The epigenetic drug MC2884, a newly generated general HAT/EZH2 inhibitor, induces apoptosis of highrisk APL blasts and reshapes their epigenomes by targeting both active and repressive marks. Together, our analysis uncovers distinctive epigenome signatures of hrAPL patients, and provides proof of concept for use of epigenome profiling coupled to epigenetic drugs to 'personalize' precision medicine.

KW - Acute promyelocytic leukemia (APL)

KW - Epi-drugs

KW - Epigenome

KW - High-risk APL

KW - PML-RARA

UR - http://www.scopus.com/inward/record.url?scp=85047385574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047385574&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25429

DO - 10.18632/oncotarget.25429

M3 - Article

AN - SCOPUS:85047385574

VL - 9

SP - 25647

EP - 25660

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 39

ER -